Clinical Trial Update: The Effect of Milnacipran on Fatigue and Quality of Life in Lupus Patients [Phase 4]

View source ↗

Summary

Phase 4 trial evaluating milnacipran for fatigue and quality of life in lupus patients has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Fibromyalgia
• Systemic Lupus Erythematosus

Drugs mentioned

• SAVELLA (milnacipran hydrochloride)

Snippet

Sponsor: Loma Linda University | Conditions: Systemic Lupus Erythematosus, Widespread Pain | Phase 4 | Status: WITHDRAWN